insights_auto
Why is CNSY down 2.50%?
Dive Deeperchevron_right
CNSY:NASDAQ
Cerenome, Inc.
$1.56
arrow_downward
-2.50%(-0.040) 1D
$1.52
arrow_downward
-2.56% (-0.040)bedtimeAfter hours
Closed: Oct 5, 4:00:01 PM GMT-4 · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for CNSY...
Open
$1.52
High
$1.59
Low
$1.48
Mkt. cap
11.84M
Avg. vol.
134.12K
Volume
0.00
52-wk high
$4.16
52-wk low
$1.48
EPS
-$4.42
Beta
1.47
Shares outstanding
7.59M
No. of employees
28
Open
$1.52
High
$1.59
Low
$1.48
Mkt. cap
11.84M
Avg. vol.
134.12K
Volume
0.00
52-wk high
$4.16
52-wk low
$1.48
EPS
-$4.42
Beta
1.47
Shares outstanding
7.59M
No. of employees
28
News stories
From web sources and news partners
Simply Wall Street
·
10 minutes ago
Manufacturing Approval Could Change The Case For Alvotech (ALVO) Stock
TradingView
·
1 hour ago
NYSE Owner Starts Gold Futures in London, a Market Without One Since 2022
MarketBeat
·
26 minutes ago
Community West Bancshares (NASDAQ:CWBC) Stock Has Consensus Price Target of $28.17
Seeking Alpha
·
1 hour ago
Cumberland's Monday Memo
Profile
Cerenome, Inc. is a clinical-stage pharmaceutical company headquartered in Houston, Texas, that develops targeted radiotherapeutics and diagnostic services for brain and central nervous system cancers. The company’s lead therapeutic candidate, marketed as REYOBIQ™, is an investigational liposomal radiopharmaceutical under clinical evaluation for recurrent glioblastoma, leptomeningeal metastases, and certain pediatric brain cancers. Cerenome also commercialized a molecular diagnostic service, CNSide®. Wikipedia
About Cerenome, Inc.